Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01 Clinical Trial Not Allowed) | PAR 19 172

Opportunity Information: Apply for PAR 19 172

Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01 Clinical Trial Not Allowed) is a National Institutes of Health (NIH) research grant opportunity (Funding Opportunity Number PAR 19-172) that supports investigator-initiated, hypothesis-driven studies focused on how the immune system adapts, compensates, and sometimes fails to adapt in ways that matter for dental, oral, and craniofacial (DOC) health and disease. The central theme is immune system plasticity, meaning the immune system's capacity to change its behavior, composition, and functional responses over time when faced with routine challenges (like microbiome shifts, mechanical stress, aging, or minor injury) as well as major disruptions (like chronic inflammation, infection, metabolic disease, or trauma). The FOA is looking for rigorous, systematic, state-of-the-art research that explains the mechanisms behind immune resilience versus immune breakdown, especially in the tissues and disease contexts that fall under DOC biology.

The scientific goal is to determine why, in some people or at some life stages, immune responses support stable tissue function and effective repair, while in other situations those same immune processes contribute to tissue degeneration, chronic inflammation, impaired healing, or destructive remodeling. Applicants are encouraged to dissect how immune cells and immune pathways dynamically maintain (or lose) their ability to carry out their protective roles when internal and external conditions change. In practical terms, that can include studying how immune programs shift across the lifespan, how they differ across individuals, and how they are influenced by local tissue environments in the mouth and craniofacial region. While the FOA description does not prescribe specific methods, it explicitly emphasizes "state-of-the-art" and "systematic" approaches, signaling an interest in modern mechanistic immunology, quantitative and systems-level strategies, and well-controlled experimental designs that can reveal causal mechanisms rather than just associations.

A key expected payoff is knowledge that enables novel immunomodulatory strategies that are personalized, meaning therapies or interventions that can be tailored to patient-specific biology rather than applied as one-size-fits-all treatments. The FOA frames this in terms of shifting the balance between degenerative and regenerative processes toward regeneration and improved disease management. In other words, the long-term translational vision is to learn how to nudge immune responses so that they support tissue robustness, promote repair, and reduce destructive inflammatory cycles in DOC conditions. This is also explicitly positioned as relevant "across the lifespan," which highlights interest in developmental stages, adulthood, and aging, and in how immune plasticity and tissue repair capacity may change over time.

This is an R01 mechanism, which typically supports substantial multi-year projects aimed at generating definitive mechanistic insights. The FOA is labeled "Clinical Trial Not Allowed," meaning the application should not propose a clinical trial as defined by NIH. Projects can still be highly relevant to human biology and patient outcomes, but they must remain within the bounds of non-clinical-trial research (for example, mechanistic studies using model systems, human biospecimens, observational or correlative human studies that do not meet the NIH definition of a clinical trial, and preclinical translational work that does not involve prospective assignment of human participants to interventions).

Eligibility is broad and includes a wide range of domestic institutions and organization types. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those categories as noted); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly highlights additional eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), tribal governments that are not federally recognized, faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, and non-domestic (non-U.S.) entities (foreign organizations), as well as regional organizations. This wide eligibility suggests NIH is open to diverse institutional settings and collaborative structures, including partnerships that connect fundamental immunology with DOC-focused clinical and translational science environments.

From an administrative perspective, the opportunity is categorized as a discretionary grant in the health area, with CFDA numbers 93.121 and 93.846, and it is issued by NIH. The source record lists an original closing date of 2022-05-07 and a creation date of 2019-01-29. The listing does not specify an award ceiling or expected number of awards in the provided data, so applicants would typically look to the full FOA text and NIH institute guidance for budget expectations, project period norms, and any institute-specific considerations.

Overall, this FOA is aimed at researchers who can explain, in a mechanistically grounded way, how immune adaptability drives either tissue stability and regeneration or chronic pathology in DOC contexts, and who can generate insights that lay the groundwork for future patient-specific immunomodulatory approaches that improve healing and long-term tissue robustness without proposing a clinical trial under this particular funding announcement.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.846.
• This funding opportunity was created on 2019-01-29.
• Applicants must submit their applications by 2022-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 19 172

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: